Contact Us

At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.

Enhanced Analytical Techniques for Molecular Characterization of CTCs and cfDNA

Speakers: Jeff Jensen, CEO, Fluxion Biosciences

About This Presentation

This presentation is from the ISLB 2020 Virtual Congress. Jeff Jensen, the CEO of Fluxion, discusses the IsoFlux CTC platform and the ERASE-Seq sequencing approach that is used for ultra sensitive somatic mutation detection from cfDNA.